Dose titration based on safety and efficacy considerations is important to optimise patient response to therapy^1,2

JAKAVI dosing may be adjusted during therapy based on changes in platelet count and response¹

Recommended dose adjustments based on response¹:

• The starting dose of JAKAVI should not be increased within the first 4 weeks of treatment and, thereafter, no more frequently than at 2-week intervals
• If efficacy is considered insufficient and platelet and neutrophil counts are adequate, the JAKAVI dose may be increased by a maximum of 5 mg twice daily

Dose titration is a critical component of optimal patient management

Continuing therapy with JAKAVI¹

• Treatment may be continued as long as benefit-risk balance remains positive
• Following interruption or discontinuation of JAKAVI, symptoms of myelofibrosis may return over a period of approximately 1 week*
• Unless abrupt discontinuation is required, gradual tapering of the dose may be considered

Next: JAK dysregulation in myelofibrosis